The Correlation between P53 and Interleukins (IL-2, IL-8) and their role in Breast Cancers P53 and IL role in breast cancer
Abstract
Background: P53 is a crucial tumor suppressor gene involved in maintaining genomic stability. This study examines the correlation between P53 expression and interleukins (IL-2, IL-8) in breast cancer (BC) patients and evaluates their potential as biomarkers.
Methods: Blood samples were collected from 40 BC patients and 20 healthy controls. Quantitative real-time PCR (RT-PCR) was used to assess P53 expression, while ELISA measured IL-2, IL-8, and P53 titers. Statistical analysis was performed using SPSS.
Results: BC patients exhibited significantly higher IL-2 (10.6 ± 3.2 pg/ml, p=0.003) and IL-8 (25.7 ± 4.5 pg/ml, p=0.001) levels compared to controls. In contrast, P53 titers were lower in BC patients (129.7 ± 55.9 pg/ml) than in controls (175.6 ± 233.8 pg/ml, p=0.02). A weak positive correlation was found between IL-2 and P53 (r=0.01), while IL-8 had a weak negative correlation with P53 (r=-0.02). RT-PCR analysis of 15 selected patients revealed a significant reduction in P53 expression (p=0.002) compared to controls.
Conclusion: The study suggests that increased IL-2 and IL-8 levels, along with decreased P53 expression, may contribute to BC progression. These cytokines could serve as potential biomarkers for prognosis and diagnosis. However, limitations include a small sample size, lack of clinical data, and weak correlations, requiring further studies with larger cohorts and comprehensive clinical profiling.
Full text article
References
Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel). 2022;14(10):2569. doi:10.3390/cancers14102569
Fasoulakis Z, Kolios G, Papamanolis V, Kontomanolis EN. Interleukins Associated with Breast Cancer. Cureus. Published online November 5, 2018. doi:10.7759/cureus.3549
Todorović-Raković N, Milovanović J. Interleukin-8 in Breast Cancer Progression. Journal of Interferon & Cytokine Research. 2013;33(10):563-570. doi:10.1089/jir.2013.0023
Al-Hasso IK. Assessment of Serum Soluble Toll-like Receptor-4 and Interleukin-8 as Biomarkers in Patients with Breast Cancer. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ). 2024;6(1):167-171. doi:10.54133/ajms.v6i1.568
Levine AJ. P53 and The Immune Response: 40 Years of Exploration—A Plan for the Future. Int J Mol Sci. 2020;21(2):541. doi:10.3390/ijms21020541
Karima Al Salihi, Ihsan Abdullah, S. L. Ang. Histological implication of p53 gene expression in oral squamous cell carcinoma. Journal of cellular cancer. 2016;8(1):60-69.
Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20(4):199-210. doi:10.1038/s41580-019-0110-x
Timofeev O. Editorial: Mutant p53 in Cancer Progression and Personalized Therapeutic Treatments. Front Oncol. 2021;11. doi:10.3389/fonc.2021.740578
Levine AJ. The many faces of p53: something for everyone. J Mol Cell Biol. 2019;11(7):524-530. doi:10.1093/jmcb/mjz026
Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24(17):2899-2908. doi:10.1038/sj.onc.1208615
Marei HE, Althani A, Afifi N, et al. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21(1):703. doi:10.1186/s12935-021-02396-8
Karima Akool Al-Salihi, S. L. Ang, A. Azlina, M.S. Farini, H. Jaffar. Immunohistochemical and molecular genetic analysis of p 53 in oral squamous cell carcinoma (scc) in Hospital University Science Malaysia: a preliminary study. Braz J Oral Sci. 2008;7(24).
Levine AJ. Spontaneous and inherited TP53 genetic alterations. Oncogene. 2021;40(41):5975-5983. doi:10.1038/s41388-021-01991-3
Philomena George. P53 HOW CRUCIAL IS ITS ROLE IN CANCER? International Journal of Current Pharmaceutical Research . 2011;3(2).
Al-Saady RK. The Impact of Body Mass Index and Some Trace Elements in Iraqi Women with Breast Cancer. J Fac Med Baghdad. 2016;57(4):312-315. doi:10.32007/jfacmedbagdad.574397
Mauro L, Naimo GD, Gelsomino L, et al. Uncoupling effects of estrogen receptor α on LKB1/AMPK interaction upon adiponectin exposure in breast cancer. The FASEB Journal. 2018;32(8):4343-4355. doi:10.1096/fj.201701315R
Matthews S, Thompson H. The Obesity-Breast Cancer Conundrum: An Analysis of the Issues. Int J Mol Sci. 2016;17(6):989. doi:10.3390/ijms17060989
Khalil S, Hatch L, Price CR, et al. Addressing Breast Cancer Screening Disparities Among Uninsured and Insured Patients: A Student-Run Free Clinic Initiative. J Community Health. 2020;45(3):501-505. doi:10.1007/s10900-019-00767-x
Heer E, Harper A, Escandor N, Sung H, McCormack V, Fidler-Benaoudia MM. Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study. Lancet Glob Health. 2020;8(8):e1027-e1037. doi:10.1016/S2214-109X(20)30215-1
Johnson KC, Houseman EA, King JE, Christensen BC. Normal breast tissue DNA methylation differences at regulatory elements are associated with the cancer risk factor age. Breast Cancer Research. 2017;19(1):81. doi:10.1186/s13058-017-0873-y
Wu C, Li M, Meng H, et al. Analysis of status and countermeasures of cancer incidence and mortality in China. Sci China Life Sci. 2019;62(5):640-647. doi:10.1007/s11427-018-9461-5
Portakal O, Özkaya Öz, Erden i̇nal M, Bozan B, Koşan M, Sayek I. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem. 2000;33(4):279-284. doi:10.1016/S0009-9120(00)00067-9
Al-Ghurabi BH. IL-2 and IL-4 Serum Levels in Breast Cancer. J Fac Med Baghdad. 2009;51(3):300-303. doi:10.32007/jfacmedbagdad.5131130
Essa S, Siddique I, Saad M, Raghupathy R. Modulation of Production of Th1/Th2 Cytokines in Peripheral Blood Mononuclear Cells and Neutrophils by Hepatitis C Virus Infection in Chronically Infected Patients. Pathogens. 2021;10(11):1519. doi:10.3390/pathogens10111519
Muraro E, Martorelli D, Turchet E, et al. A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapies. Breast Cancer Research. 2011;13(6):R117. doi:10.1186/bcr3060
WANG YC, WANG ZH, YEN JH, et al. The Contribution of Interleukin-8 Rs4073 Genotypes to Triple Negative Breast Cancer Risk in Taiwan. Anticancer Res. 2022;42(8):3799-3806. doi:10.21873/anticanres.15870
Al-Hasso IK. Assessment of Serum Soluble Toll-like Receptor-4 and Interleukin-8 as Biomarkers in Patients with Breast Cancer. Al-Rafidain Journal of Medical Sciences ( ISSN 2789-3219 ). 2024;6(1):167-171. doi:10.54133/ajms.v6i1.568
Mohsin SAM, Al-Thwani AN. Clinical importance of interleukin-8 concentration in Iraqi breast cancer patients. . Iraqi J Biotechnol 2012;11(1):133-140. 2012;11(1):133-140.
MATSUI T, OJIMA A, HIGASHIMOTO Y, TAIRA J, FUKAMI K, YAMAGISHI SI. Pigment epithelium-derived factor inhibits caveolin-induced interleukin-8 gene expression and proliferation of human prostate cancer cells. Oncol Lett. 2015;10(4):2644-2648. doi:10.3892/ol.2015.3568
Ghazwan Sabah Kamel, Salih Mahdi Salman, Walaa Najim Abood. Evaluation of P53 and Some Blood Parameters In Women Diagnosed With Breast Cancer. Diyala Journal of Medicine . 2019;17(1).
Al-Hassan Ahmed AA. Detection of serum anti-p53 antibodies in breast cancer patients. Al-Mustansiriyah Journal of Science . Published online 2011:7-12.
Børresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003;21(3):292-300. doi:10.1002/humu.10174
Pützer BM, Bramson JL, Addison CL, et al. Combination Therapy with Interleukin-2 and Wild-Type p53 Expressed by Adenoviral Vectors Potentiates Tumor Regression in a Murine Model of Breast Cancer. Hum Gene Ther. 1998;9(5):707-718. doi:10.1089/hum.1998.9.5-707
Yuan A, Yu CJ, Luh KT, Kuo SH, Lee YC, Yang PC. Aberrant p53 Expression Correlates With Expression of Vascular Endothelial Growth Factor mRNA and Interleukin-8 mRNA and Neoangiogenesis in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 2002;20(4):900-910. doi:10.1200/JCO.2002.20.4.900
Feroz W, Sheikh AMA. Exploring the multiple roles of guardian of the genome: P53. Egyptian Journal of Medical Human Genetics. 2020;21(1):49. doi:10.1186/s43042-020-00089-x
Schumacher B, Pothof J, Vijg J, Hoeijmakers JHJ. The central role of DNA damage in the ageing process. Nature. 2021;592(7856):695-703. doi:10.1038/s41586-021-03307-7
Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022;29(5):946-960. doi:10.1038/s41418-022-00988-z
Gasco M, Shami S, Crook T. The p53 pathway in breast cancer. Breast Cancer Research. 2002;4(2):70. doi:10.1186/bcr426
Marei HE, Althani A, Afifi N, et al. p53 signaling in cancer progression and therapy. Cancer Cell Int. 2021;21(1):703. doi:10.1186/s12935-021-02396-8
D Kandioler-Eckersberger, C Ludwig, M Rudas, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. Clin Cancer Res . 2000;6(1):50-56.
Mohan A, Jindal B, Thakral RK, Ansari V, Sharma VK. Role of p53 as a prognostic marker in breast carcinoma and its correlation with tumor size, tumor grade and lymph node metastasis. Indian Journal of Pathology and Oncology. 2020;7(3):378-383. doi:10.18231/j.ijpo.2020.076
Authors
Copyright (c) 2025 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.